MUC16 and cancer: For improving the cancer diagnosis and management capabilities of the pathological condition, this signature biomarker (MUC3A/MUC4/MUC13/MUC16) plays a constructive role by enabling the real‐time monitoring through the noninvasive technique, paving the path for better patient outcomes through early diagnosis and targeted treatment methods.